# Sporos Bioventures

> Sporos Bioventures is a Houston-based private biotechnology company that builds and operates a portfolio of oncology and immune-disease startups under one roof. Rather than launching companies one at a time, Sporos pools capital, drug-discovery infrastructure, and operational expertise across multiple programs - including Tvardi Therapeutics, Asylia Therapeutics, Nirogy Therapeutics, Stellanova Therapeutics, and its internal Sporos BioDiscovery group - to move targeted cancer therapies from idea to early clinical trials faster and with less duplicated risk.

- **Founded:** 2021
- **Headquarters:** Houston, Texas, United States
- **Founders:** Peter Feinberg (Co-Founder & Board Director (Founding Partner, Boxcar Partners; BridgeBio Pharma co-founder)), Joseph Kekst (Co-Founder), Ronald DePinho (Chair, Strategic Advisory Council (former MD Anderson president)), Jeno Gyuris (Chief Scientific Officer), Michael Wyzga (Founding CFO (former Genzyme CFO))
- **Team size:** ~8 employees (core Sporos Bioventures team; additional staff across portfolio companies)
- **Products:** Sporos BioDiscovery, Tvardi Therapeutics, Asylia Therapeutics, Nirogy Therapeutics, Stellanova Therapeutics
- **Notable:** Launched in May 2021 with a $38.1 million Series A financing., Assembled a portfolio of four oncology/immune-disease companies plus an internal discovery group at launch., Tvardi's TTI-101 (STAT3 inhibitor) advanced into Phase 1 with durable responses across multiple tumor types.

## Products & services

- **Sporos BioDiscovery** — Internal discovery group focused on small molecules and antibody therapeutics; presented preclinical data on SPR1, a next-generation TEAD inhibitor, at AACR 2024.
- **Tvardi Therapeutics** — Portfolio company; lead asset TTI-101 is an oral STAT3 inhibitor with clinical activity and durable responses across multiple tumor types and fibrosis indications.
- **Asylia Therapeutics** — Portfolio company developing targeted therapies in oncology.
- **Nirogy Therapeutics** — Portfolio company focused on cancer and immune disease targets, including transporter biology.
- **Stellanova Therapeutics** — Portfolio company developing novel oncology programs.

## Achievements

- Launched in May 2021 with a $38.1 million Series A financing.
- Assembled a portfolio of four oncology/immune-disease companies plus an internal discovery group at launch.
- Tvardi's TTI-101 (STAT3 inhibitor) advanced into Phase 1 with durable responses across multiple tumor types.
- Sporos BioDiscovery presented preclinical findings on SPR1, a next-generation TEAD inhibitor, at AACR 2024.
- Presented at the Oppenheimer 33rd Annual Healthcare Conference.

## Latest updates

- **2024-03** — Sporos BioDiscovery announced it would present preclinical findings on SPR1, a next-generation TEAD inhibitor, at the AACR Annual Meeting 2024.
- **2022-09** — Stephen Rubino, PhD, MBA, appointed Chief Executive Officer.
- **2021-05** — Company launched publicly with the close of a $38.1 million Series A financing.

## Links

- Website: https://sporosbioventures.com
- LinkedIn: https://www.linkedin.com/company/sporos-bioventures

---

Profile page: https://yespress.io/sporos-bioventures
Published by YesPress — https://yespress.io
Last updated: 2026-06-12